Loading stock data…
$23.67+1.54 (+6.96%)
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Nurix Therapeutics, Inc. in the Healthcare sector is trading at $23.67 with a market capitalization of $2.7B. Wall Street consensus targets $34.36 (14 analysts), implying a +45.2% move over the next 12 months. The stock is currently 16% below its 52-week high of $28.23, remaining 19.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $9.04M↑ | $6.25M↓ | $13.58M↑ | $7.89M↓ | $44.06M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$94.20M↓ | -$92.50M↓ | -$83.09M↑ | -$91.39M↓ | -$48.32M |
| Net Income | -$89.53M↓ | -$87.17M↓ | -$78.22M↑ | -$86.42M↓ | -$43.46M |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The ...